2025. Pembrolizumab in PD-L1-positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis Survival Benefits and Immune-related Toxicity Events Patterns: Original scientific article. ADMET and DMPK. (Oct. 2025), 2956. DOI:https://doi.org/10.5599/admet.2956.